LIQUID DOSAGE FORMS OF ISOTRETINOIN

1 . A pharmaceutical solution comprising isotretinoin or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier.

2 . The pharmaceutical solution according to claim 1 , wherein the carrier comprises a lipophilic carrier or a combination of lipophilic/hydrophilic carriers.

3 . The pharmaceutical solution according to claim 2 , wherein the lipophilic carrier comprises fatty acid esters, fatty acids, fatty alcohols, vegetable oil or a combination thereof.

4 . The pharmaceutical solution according to claim 3 , wherein the fatty acid ester comprises a polyol ester of medium chain fatty acid selected from esters and mixed esters of glycerol, propylene glycol, polyglycerol and polyethylene glycol with medium chain fatty acids or mixtures thereof.

5 . The pharmaceutical solution according to claim 3 , wherein the fatty acid comprises C 6 -C 20 saturated, mono, di-unsaturated acid or mixtures thereof.

6 . The pharmaceutical solution according to claim 3 , wherein the fatty alcohol comprises C 6 -C 20 saturated, mono, di-unsaturated alcohol or mixtures thereof.

7 . The pharmaceutical solution according to claim 3 , wherein the vegetable oil comprises kernel oil, almond oil, groundnut oil, olive oil, soybean oil, safflower oil, sunflower oil, palm oil, sesame oil, canola oil or corn oil or mixtures thereof.

8 . The pharmaceutical solution according to claim 2 , wherein the hydrophilic carrier comprises monohydric alcohols, glycols, polyols, glycerols or combination thereof.

9 . The pharmaceutical solution according to claim 1 , wherein the isotretinoin or a salt thereof is present in an amount of about 0.01% to about 3.0% by weight of the composition.

10 . The pharmaceutical solution according to claim 1 , further comprising one or more pharmaceutically acceptable excipients selected from one or more of antioxidants, chelating agents, preservatives, colors, sweeteners or flavors or mixtures thereof.

11 . The pharmaceutical solution according to claim 1 , wherein said solution is stable during storage at 40° C.±2° C. and 75%±5% Relative Humidity; and 25° C.±2° C. and 60%±5% Relative Humidity.

12 . The pharmaceutical solution according to claim 1 , that when administered to a human patient in a fed state, exhibits a maximum plasma concentration (C max ) of isotretinoin comparable to that exhibited under fasting state.

13 . A process of preparing a pharmaceutical solution of isotretinoin comprising the steps of:

(i) dissolving isotretinoin in a carrier by continuous stirring at room temperature, or at higher temperatures, till a homogenous solution is formed; and

(ii) cooling the solution of step (i) to room temperature, optionally, adding one or more excipients.

14 . A process of preparing a pharmaceutical solution of isotretinoin comprising the steps of:

(i) dissolving one or more excipients in a carrier by continuous stirring;

(ii) dissolving isotretinoin in the solution of step (i) by continuous stirring at room temperature, or at higher temperatures, till a homogenous solution is formed; and

(iii) cooling the solution of step (ii) to room temperature.

15 . A process of preparing a pharmaceutical solution of isotretinoin comprising the steps of:

(i) dissolving one or more excipients in a carrier by continuous stirring;

(ii) suspending the isotretinoin in the solution of step (i) under continuous stiffing and milling the suspension to form a homogenous micronized suspension;

(iii) diluting the suspension of step (ii) with a carrier to the desired concentration

(iv) diluting the suspension of step (iii) with a suitable carrier to form a clear solution of isotretinoin at the time of administration.

16 . The solution according to claim 1 , wherein the pharmaceutical solution is suitable for packaging into multi-dose or unit-dose packages without producing discoloration or degradation.

17 . A method of treating acne, musculoskeletal and connective tissue inflammations, emphysema, ulcerating diseases, cervical tumors in HIV positive women, lung cancer in smokers, skin cancer, neuroblastoma, recurrent prostrate cancer, leukemia, high-grade glioma, head and neck cancers, multiple myeloma, gram-negative folliculitis, recalcitrant rosacea, pyoderma faciale, generalized lichen planus, psoriasis, cutaneous lupus erythematosus and acne fulminans, squamous cell carcinoma, cutaneous photoaging and other off-label indications of isotretinoin, by administering a pharmaceutical solution comprising isotretinoin or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier.